BMC Medical Co., Ltd. (SHE:301367)
China · Delayed Price · Currency is CNY 67.75
+1.05 (1.57%)
At close: May 8, 2026
BMC Medical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,202 | 1,158 | 842.24 | 1,119 | 1,413 | 661.08 |
Other Revenue | 1.36 | 1.36 | 1.24 | 3.01 | 2.62 | 1.42 |
| 1,203 | 1,159 | 843.48 | 1,122 | 1,415 | 662.5 | |
Revenue Growth (YoY) | 31.26% | 37.46% | -24.85% | -20.70% | 113.64% | 18.20% |
Cost of Revenue | 563.22 | 555.87 | 449.31 | 619.28 | 828.15 | 377.5 |
Gross Profit | 640 | 603.55 | 394.17 | 503.14 | 587.22 | 285 |
Selling, General & Admin | 295.97 | 256.16 | 172.58 | 142.35 | 131.68 | 95.52 |
Research & Development | 142.05 | 139.12 | 124.62 | 116.98 | 72.86 | 48.28 |
Other Operating Expenses | -17.16 | -17.43 | -2.76 | -23.5 | -19.3 | -9.51 |
Operating Expenses | 423.26 | 380.25 | 297.2 | 238.62 | 189.01 | 134.53 |
Operating Income | 216.74 | 223.31 | 96.98 | 264.51 | 398.2 | 150.47 |
Interest Expense | -4.97 | -4.97 | -2.85 | -1.36 | -0.46 | -0.2 |
Interest & Investment Income | 60.81 | 57.61 | 62.36 | 63.36 | 20.09 | 11.56 |
Currency Exchange Gain (Loss) | -10.97 | -10.97 | 4.51 | -0.4 | 11.98 | -3.67 |
Other Non Operating Income (Expenses) | -20.84 | -1.11 | -0.85 | 0.2 | -0.26 | -0.53 |
EBT Excluding Unusual Items | 240.77 | 263.87 | 160.14 | 326.31 | 429.55 | 157.64 |
Gain (Loss) on Sale of Investments | -18.42 | -7.82 | 10.44 | - | - | - |
Gain (Loss) on Sale of Assets | 0.26 | 0.26 | 0.19 | 0.48 | 0.02 | - |
Asset Writedown | 0.12 | -0.83 | -3.06 | -0.02 | - | -0.01 |
Other Unusual Items | 5.89 | 5.89 | 8.42 | 7.27 | 5.52 | 6.24 |
Pretax Income | 228.61 | 261.36 | 176.14 | 334.03 | 435.09 | 163.86 |
Income Tax Expense | 30.39 | 30.1 | 17.54 | 34.2 | 54.06 | 18.18 |
Earnings From Continuing Operations | 198.22 | 231.26 | 158.6 | 299.83 | 381.03 | 145.68 |
Minority Interest in Earnings | -6.07 | -5.6 | -3.22 | -2.49 | -0.74 | - |
Net Income | 192.15 | 225.66 | 155.38 | 297.34 | 380.3 | 145.68 |
Net Income to Common | 192.15 | 225.66 | 155.38 | 297.34 | 380.3 | 145.68 |
Net Income Growth | 8.31% | 45.23% | -47.74% | -21.81% | 161.05% | -36.07% |
Shares Outstanding (Basic) | 89 | 89 | 89 | 90 | 71 | 67 |
Shares Outstanding (Diluted) | 89 | 89 | 89 | 90 | 71 | 67 |
Shares Change (YoY) | -0.33% | -0.52% | -0.29% | 26.33% | 5.67% | -0.16% |
EPS (Basic) | 2.16 | 2.54 | 1.74 | 3.32 | 5.36 | 2.17 |
EPS (Diluted) | 2.16 | 2.54 | 1.74 | 3.32 | 5.36 | 2.17 |
EPS Growth | 8.67% | 45.98% | -47.59% | -38.11% | 147.04% | -35.96% |
Free Cash Flow | 88.19 | 97.94 | 138.16 | 126.98 | 351.46 | 94.38 |
Free Cash Flow Per Share | 0.99 | 1.10 | 1.55 | 1.42 | 4.96 | 1.41 |
Dividend Per Share | 0.660 | 0.660 | 0.400 | 1.000 | 1.429 | - |
Dividend Growth | 65.00% | 65.00% | -60.00% | -30.00% | - | - |
Gross Margin | 53.19% | 52.06% | 46.73% | 44.83% | 41.49% | 43.02% |
Operating Margin | 18.01% | 19.26% | 11.50% | 23.57% | 28.13% | 22.71% |
Profit Margin | 15.97% | 19.46% | 18.42% | 26.49% | 26.87% | 21.99% |
Free Cash Flow Margin | 7.33% | 8.45% | 16.38% | 11.31% | 24.83% | 14.24% |
EBITDA | 227.82 | 234.68 | 109.53 | 274.46 | 403.85 | 155.09 |
EBITDA Margin | 18.93% | 20.24% | 12.98% | 24.45% | 28.53% | 23.41% |
D&A For EBITDA | 11.08 | 11.38 | 12.55 | 9.95 | 5.65 | 4.62 |
EBIT | 216.74 | 223.31 | 96.98 | 264.51 | 398.2 | 150.47 |
EBIT Margin | 18.01% | 19.26% | 11.50% | 23.57% | 28.13% | 22.71% |
Effective Tax Rate | 13.29% | 11.52% | 9.96% | 10.24% | 12.42% | 11.09% |
Revenue as Reported | 1,159 | 1,159 | 843.48 | 1,122 | 1,415 | 662.5 |
Advertising Expenses | - | - | - | 39.67 | 6.74 | 4.26 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.